Stoke Therapeutics Inc (STOK) P/E Multiple
Stoke Therapeutics is developing genetic therapies through partnerships with pharma behemoths, which accelerates testing. The company's P/E dynamics visualize the market valuation of these successes, where -7.50 shows the current value of the metric. Cost optimization through the outsourcing of production and IT infrastructure supports R&D efficiency, while positive data on Dravet syndrome therapy serves as the primary driver of value growth.
Comprehensive metric breakdowns and analytics for Stoke (STOK)
- market price and analyst price targets:
- market capitalization details:
- company book value details:
- debt and solvency information:
Aggregate Debt to Capital Stoke Therapeutics|STOK - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Stoke Corp|STOK - Company Aggregate Debts|Debts to Book Value Stoke Therapeutics, Inc.|STOK - Company Long-Term Debt|Company Short-Term Loans and Borrowings Stoke Therapeutics|Quick Ratio stoketherapeutics.com
- business earnings and investment ratios data:
STOK - Company Net Income|Forward Earnings Stoke Therapeutics|STOK - P/E Multiple|Projected Price to Earnings Ratio Stoke Therapeutics Inc|STOK - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Stoke Therapeutics, Inc.|STOK - Operating profit before deduction of amortization|Earnings per share for the last four quarters Stoke Therapeutics|STOK - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months stoketherapeutics.com|STOK - Earnings growth in current year|Expected earnings per share growth for next year Stoke Therapeutics
Summary company analysis:STOK (stoketherapeutics.com)
The P/E ratio determines the market value of a business relative to its annual net income, allowing an investor to assess the investment payback period and avoid value traps. For Stoke Therapeutics (STOK) and its lifelong RNA-based therapies, the current P/E valuation reflects market expectations of stable demand and long-term monetization of rare diseases.
Analysis of competing companies
Market Cap to Earnings Tempus AI Inc TEM|Price to Earnings Ratio Qiagen (QGEN)|P/E Multiple Ionis Pharmaceuticals, Inc. (IONS)|P/E Multiple RGEN (Repligen Corp.)|Avidity Corp (RNA) - Market Cap to Earnings|CRSP: Price to Earnings Ratio|Company Value to Net Income WGS (genedx.com)|RARE (Ultragenyx) - Price to Earnings Ratio|BEAM: Market Price to Net Income Ratio|SRPT (Sarepta Therapeutics Inc) - P/E Multiple|TWST: Company Value to Net Income|P/E Multiple TXG|NTLA - Market Cap to Earnings|Price to Earnings Ratio BioLife Solutions BLFS|Company Value to Net Income WVE|Maze Tx - P/E Multiple|SION - P/E Multiple|Prime Medicine, Inc. (PRME) - Price to Earnings Ratio|Market Cap to Net Income TSHA (tayshagtx.com)|QURE (uniQure) - P/E Multiple|Market Cap to Earnings MeiraGTx Holdings MGTX|Price to Earnings Ratio RGNX (Regenxbio)|P/E Multiple Solid Corp (SLDB)|Ocugen, Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio PACB (pacb.com)|Benitec Biopharma - P/E Multiple|Business Payback Period Design Therapeutics Inc DSGN|RCKT: P/E Multiple|Price to Earnings Ratio 4D Molecular Corp|Price to Earnings Ratio Lexeo Therapeutics Inc.|Korro Bio, Inc (KRRO) - Business Payback Period|Price to Earnings Ratio Editas Medicine (EDIT)|Business Payback Period Silence Therapeutics PLC|ProQR Therapeutics - Price to Earnings Ratio|Market Price to Net Income Ratio CDXS (Codexis Inc)|SGMO - Price to Earnings Ratio|Market Cap to Earnings Nautilus Biotechnology|Metagenomi (MGX) - Price to Earnings Ratio|precisionbiosciences.com (DTIL) - P/E Multiple|GBIO (Generation Bio Co) - P/E Multiple|Price to Earnings Multiple BOLD (Boundless Bio Inc)|Price to Earnings Ratio Exicure, Inc. (XCUR)|imunon.com - Price to Earnings Multiple|P/E Multiple PHIO (Phio Pharmaceuticals Corp.)|P/E Multiple Mustang Bio Inc MBIO|RNAZ - Price to Earnings Ratio|Business Payback Period Bionano Genomics, Inc. BNGO|APDN (Applied DNA Sciences) - Price to Earnings Ratio|BLUE: Market Price to Net Income Ratio|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd|Market Cap to Earnings Omega Therapeutics Inc OMGA|Price to Earnings Ratio Singular Genomics Systems Inc (OMIC)|P/E Multiple Regulus (RGLS)|P/E Multiple SYRS (Syros Pharmaceuticals)|telesisbio.com (TBIO) - Market Cap to Earnings|TCON: Price to Earnings Ratio|Company Value to Net Income UBX (Unity Biotechnology Inc.)
